Operating cash flow of -$44.3M in 2026Q3 tracks net loss closely at an OCF-to-net-income ratio of 0.89, with no dividends, buybacks, or acquisitions, so all capital raised is being consumed by operations.
Oruka Therapeutics, Inc. (ORKA) cash flow statement — 21-year operating, investing & financing cash flows
| Metric | TTM | Dec'25 | Dec'24 | Dec'23 | Dec'22 | Dec'21 | Dec'20 | Dec'19 | Dec'18 | Dec'17 | Dec'16 | Dec'15 | Dec'14 | Dec'13 | Dec'12 | Dec'11 | Dec'10 | Dec'09 | Dec'08 | Dec'07 | Dec'06 | Dec'05 |
|---|
| Cash from Operations | -123.64M | -88.21M | -57.84M | - | -10.91M | -18.76M | -7.72M | -4.8M | -8.24M | -17.47M | -14.99M | -10.53M | -9.41M | -5.29M | -4.08M | -6.96M | -8.32M | -41.73M | -18.4M | -45.96M | -37.06M | -59.03M |
| Operating CF Margin % | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | -98.07% | -953.19% | -10832.11% |
| Operating CF Growth % | -181.45% | -52.51% | - | - | 41.84% | -142.87% | -60.9% | 41.76% | 52.82% | -16.58% | -42.27% | -11.99% | -77.87% | -29.67% | 41.4% | 16.4% | 80.05% | -126.76% | 59.96% | -24.01% | 37.22% | - |
| Net Income | -152.57M | -105.43M | -83.72M | - | -9.93M | -19.32M | -9.74M | -5.48M | -7.93M | -18.49M | -16.44M | -11.45M | -9.69M | -6.94M | -4.32M | -5.36M | -8.42M | -9.14M | -19.43M | -12.3M | -132.78M | -71.61M |
| Depreciation & Amortization | 163K | 83K | 27K | - | 114K | 91K | 93K | 89K | 22K | 27K | 24K | 19K | 12K | 26K | 43K | 602K | 338K | 457K | 220K | 2.34M | 3.18M | 2.67M |
| Stock-Based Compensation | 9.13M | 0 | 0 | - | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Deferred Taxes | 0 | 0 | 0 | - | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | -2.28M | 0 | 0 | 0 | 0 |
| Other Non-Cash Items | 14.93M | 19.7M | 14.27M | - | 561K | 497K | 43K | 151K | 275K | 906K | 1.03M | 788K | 714K | 283K | 306K | -1.68M | 191K | -17.63M | 670K | 12.55M | 38.76M | -33K |
| Working Capital Changes | 4.71M | -2.56M | 11.59M | - | -1.66M | -28K | 1.88M | 441K | -608K | 85K | 400K | 104K | -443K | 1.34M | -107K | -521K | -433K | -13.13M | 140K | -48.55M | 53.77M | 9.94M |
| Change in Receivables | 0 | 0 | 0 | - | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 7.97M | -7.35M | -1.07M |
| Change in Inventory | 0 | 0 | 0 | - | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 360K |
| Change in Payables | 12.17M | 693K | 3.46M | - | -783K | -411K | 1.1M | 188K | -392K | -583K | 0 | 0 | 0 | 532K | -195K | -128K | -145K | -2.46M | -865K | -4.27M | 2.11M | 1.81M |
| Cash from Investing | -606.8M | -96.75M | -330.13M | - | -2K | -43K | -19K | -4K | 3.05M | 12.93M | -16.41M | -11K | -19K | -32K | 0 | 2.01M | 265K | 45.63M | -2.52M | 21.09M | -62.06M | -1.18M |
| Capital Expenditures | -219K | -209K | -189K | - | -2K | -43K | -19K | -4K | -4K | -3K | -12K | -11K | -19K | -32K | 0 | -19K | -4K | -185K | -1.34M | -381K | -2.44M | -2.57M |
| CapEx % of Revenue | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | 0.81% | 62.81% | 471.56% |
| Acquisitions | 0 | 0 | 0 | - | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 25K | 6K | 322K | 5K | 136K | 540K | 0 |
| Investments | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
| Other Investing | 0 | 0 | 0 | - | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 2M | 0 | 0 | -1.19M | -6M | 0 | 0 |
| Cash from Financing | 830.71M | 170.31M | 449.54M | - | 0 | 23.09M | 48.45M | 6.56M | 3.1M | 5.85M | 0 | 33.99M | 8.02M | 19.16M | 1.05M | 3.87M | 7.32M | -3.89M | 12.8M | -3.4M | 121.69M | 81.16M |
| Debt Issued (Net) | 0 | 0 | 0 | - | 0 | 0 | -408K | -349K | 0 | 0 | 0 | 0 | 0 | -174K | -134K | 0 | 0 | -4M | 12.75M | -3.83M | -5.59M | -3.38M |
| Equity Issued (Net) | 830.71M | 170.31M | 449.54M | - | 0 | 23.09M | 48.86M | 6.91M | 3.42M | 6.1M | 0 | 34.19M | 8.2M | 19.33M | 1.19M | 4.02M | 7.66M | 114K | 54K | 426K | 130.04M | 84.35M |
| Dividends Paid | 0 | 0 | 0 | - | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Share Repurchases | 0 | 0 | 0 | - | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Other Financing | 0 | 0 | 0 | - | 0 | 0 | 0 | 0 | -311K | -256K | 0 | -193K | -179K | 0 | 0 | -146K | -338K | 0 | 0 | 0 | -2.75M | 191K |
| Net Change in Cash | 100.27M | -14.64M | 24.14M | - | -10.91M | 4.29M | 40.71M | 1.75M | -2.09M | 1.3M | -31.4M | 23.45M | -1.4M | 13.84M | -3.02M | -1.08M | -738K | 23K | -24.32M | -28.27M | 22.57M | 37.76M |
| Free Cash Flow | -123.86M | -88.42M | -58.03M | - | -10.91M | -18.8M | -7.74M | -4.8M | -8.25M | -17.48M | -15M | -10.54M | -9.43M | -5.32M | -4.08M | -6.98M | -8.33M | -41.91M | -19.75M | -46.34M | -39.5M | -61.6M |
| FCF Margin % | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | -98.89% | -1016% | -11303.67% |
| FCF Growth % | -46.41% | -52.38% | - | - | 41.96% | -142.83% | -61.17% | 41.74% | 52.8% | -16.51% | -42.24% | -11.88% | -77.16% | -30.46% | 41.56% | 16.21% | 80.13% | -112.26% | 57.39% | -17.31% | 35.88% | - |
| FCF per Share | -1.73 | -1.94 | -3.46 | - | -0.76 | -1.35 | -1.64 | -43.64 | -128.64 | -361.85 | -357.31 | -362.16 | -695.11 | -932.19 | -2774.15 | -6309.22 | -8881.82 | -53609.64 | -999999.00 | -157646.26 | -139302.30 | -270782.02 |
| FCF Conversion (FCF/Net Income) | 0.81x | 0.84x | 0.69x | - | 1.10x | 0.97x | 0.79x | 0.88x | 1.04x | 0.94x | 0.91x | 0.92x | 0.97x | 0.76x | 0.94x | 1.30x | 0.99x | 4.57x | 0.95x | 3.74x | 0.28x | 0.82x |
| Interest Paid | 0 | 0 | 0 | - | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Taxes Paid | 0 | 0 | 0 | - | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
Quick answers to the most common questions about buying ORKA stock.
Oruka Therapeutics, Inc. (ORKA) generated $-88.2M in net cash from operating activities in 2025. This reflects the cash generated directly from core business operations.
Oruka Therapeutics, Inc. (ORKA) reported negative free cash flow of $88.4M in 2025, indicating capital requirements exceeded cash from operations.
Oruka Therapeutics, Inc. (ORKA) spent $0.2M on capital expenditures in 2025. CapEx represents the cash invested in physical assets like property, plant, and equipment to maintain or grow the business.
Key Metrics
Top Statement Risk
Dilutive financing dependence risk
Cash Losses Track Accounting Losses Closely
According to recent SEC filings, ORKA's operating cash flow of -$44.3M in 2026Q3 against a net loss of -$50.0M yields an OCF-to-net-income ratio of 0.89, indicating that most reported losses are consuming cash rather than being offset by non-cash charges.
The gap between net loss and operating cash flow is narrower than the $9.1M of stock-based compensation alone would imply, suggesting that the remaining non-cash items are modest and the loss is largely a real cash outflow. Over the ten quarters provided, the ratio has ranged from 0.12 to 1.22, with the 2024Q2 figure reflecting a timing distortion rather than a durable pattern. Investors should monitor whether the ratio stabilizes near 0.7 to 0.9, which would indicate that the cash burn is structural and driven by clinical spending rather than accounting noise.
Free Cash Outflow Accelerating With Clinical Spend
Based on reported figures, ORKA's free cash flow deteriorated from -$2.6M in 2024Q2 to -$44.4M in 2026Q3, a roughly seventeen-fold increase in quarterly cash consumption over six quarters.
Because the company reports no revenue, free cash flow margin is data unavailable, and the absolute burn rate is the only meaningful trajectory measure. The acceleration appears consistent with the step-up in R&D expense noted in the income statement analysis, suggesting late-stage or expanded trial activity. This trend may indicate that the current cash balance of roughly $46.9M covers little more than one additional quarter at the latest burn rate, warranting close attention to financing timing.
Negligible Capital Intensity Confirms Asset-Light Model
As reported in financial statements, ORKA's capital expenditures remained between $0 and $171K per quarter across the period, a rounding error relative to its $44.3M quarterly operating cash outflow.
The minimal capex profile is consistent with a company that outsources discovery to Paragon and relies on contract manufacturers rather than owned production facilities. D&A of roughly $20K to $49K per quarter corroborates the absence of a meaningful fixed asset base. This suggests that the cash economics are driven almost entirely by operating expense rather than by capital formation, and that the risk profile is one of execution spending rather than balance sheet asset depreciation.
No Capital Returned, All Cash Consumed by Operations
Based on reported figures, ORKA paid no dividends, executed no share repurchases, and recorded no net acquisition outflows across the ten quarters, so all deployed cash went toward operating activities.
The absence of shareholder distributions is expected for a pre-revenue clinical-stage company and does not in itself signal weakness. However, the absence of capital returns combined with a burn rate that rose sharply means every dollar raised is being consumed by operations, leaving no buffer. Investors should monitor future financing terms, since the next capital raise will likely determine dilution levels and the company's ability to reach its next clinical readout.
Cumulative Losses Dwarf Reported Cash Position
Based on reported figures, the cumulative operating cash outflow across the ten quarters exceeds $260M, against a reported cash balance of approximately $46.9M, implying the company has depended heavily on external financing to date.
The cumulative gap between net income and operating cash flow is relatively consistent in direction, with losses in every quarter, so the divergence is primarily a question of scale rather than accounting quality. The historical financing required to fund this burn is not fully visible in the provided data, so the source and timing of past capital raises remain data unavailable. This pattern suggests the business model is structurally dependent on capital markets until a commercial product or partnership generates cash.
Non-Cash Charges Could Obscure True Burn
Based on reported figures, stock-based compensation of $9.1M in 2026Q3 and $10.2M in 2025Q3 may flatter the operating cash picture, so underlying cash needs could differ from headline burn depending on how awards are settled.
Stock-based compensation is excluded from operating cash outflow, so the reported burn understates the economic cost of retaining specialized scientific talent. If equity awards are increasingly replaced with cash bonuses or retention payments, operating cash burn could rise beyond the current trajectory. Investors should monitor the composition of R&D and SG&A expense and any shift in compensation mix, as this warrants further investigation rather than being treated as a settled conclusion.